SCHEMBL23336002

SCHEMBL23336002

C[C@@H](CO)Nc1cn[nH]c(=O)c1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TIPARP Q7Z3E1 19/20 0.52
PARP14 Q460N5 2/20 0.49
PARP12 Q9H0J9 2/20 0.49
TNKS2 Q9H2K2 2/20 0.49
PARP11 Q9NR21 2/20 0.49
PARP2 Q9UGN5 2/20 0.49
TNKS O95271 1/20 0.49
PARP10 Q53GL7 1/20 0.49
PARP1 P09874 2/20 0.48
CYP2C9 P11712 1/20 0.48
PARP16 Q8N5Y8 1/20 0.48
PARP4 Q9UKK3 1/20 0.48
PARP3 Q9Y6F1 1/20 0.48
HDAC1 Q13547 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24640494 1.00 TIPARP (0.52) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL24640475 1.00 TIPARP (0.52) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL29210212 0.86 TIPARP (0.49) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL24962326 0.86 TIPARP (0.49) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL30196255 0.84 TIPARP (0.46) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL24687628 0.84 TIPARP (0.55) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL24640899 0.84 TIPARP (0.44) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL24640495 0.83 TIPARP (0.42) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL24687782 0.83 TIPARP (0.54) TIPARPPARP14PARP12TNKS2PARP11
SCHEMBL30286463 0.81 TIPARP (0.55) TIPARPPARP14PARP12TNKS2PARP11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4289845-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2023-12-13 EP disclosed
WO-2022242750-A1 PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2022-11-24 WO disclosed
WO-2022170974-A1 TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-08-18 WO disclosed
US-20210130342-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130342-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 TIPARP 152/4885PARP14 10/4885PARP12 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.